Tenaya Therapeutics Inc. (TNYA)
Tenaya Therapeutics Statistics
Share Statistics
Tenaya Therapeutics has 162.58M shares outstanding. The number of shares has increased by 107.07% in one year.
| Shares Outstanding | 162.58M |
| Shares Change (YoY) | 107.07% |
| Shares Change (QoQ) | 105.23% |
| Owned by Institutions (%) | 50.66% |
| Shares Floating | 134.09M |
| Failed to Deliver (FTD) Shares | 28.2K |
| FTD / Avg. Volume | 0.84% |
Short Selling Information
The latest short interest is 11.48M, so 14.49% of the outstanding shares have been sold short.
| Short Interest | 11.48M |
| Short % of Shares Out | 14.49% |
| Short % of Float | 17.49% |
| Short Ratio (days to cover) | 1.95 |
Valuation Ratios
The PE ratio is -1.09 and the forward PE ratio is -0.85. Tenaya Therapeutics's PEG ratio is 0.05.
| PE Ratio | -1.09 |
| Forward PE | -0.85 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 1.31 |
| P/FCF Ratio | -1.33 |
| PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tenaya Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.22, with a Debt / Equity ratio of 0.15.
| Current Ratio | 4.22 |
| Quick Ratio | 4.22 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.15 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.15M |
| Employee Count | 97 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -88.65% in the last 52 weeks. The beta is 2.99, so Tenaya Therapeutics's price volatility has been higher than the market average.
| Beta | 2.99 |
| 52-Week Price Change | -88.65% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 2.06 |
| Relative Strength Index (RSI) | 35.26 |
| Average Volume (20 Days) | 3.37M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -115.95M |
| Net Income | -111.13M |
| EBITDA | -115.95M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.31 |
Balance Sheet
The company has 4.32M in cash and 13.61M in debt, giving a net cash position of -9.29M.
| Cash & Cash Equivalents | 4.32M |
| Total Debt | 13.61M |
| Net Cash | -9.29M |
| Retained Earnings | -514.41M |
| Total Assets | 119.94M |
| Working Capital | 51.4M |
Cash Flow
In the last 12 months, operating cash flow was -90.5M and capital expenditures -1.02M, giving a free cash flow of -91.53M.
| Operating Cash Flow | -90.5M |
| Capital Expenditures | -1.02M |
| Free Cash Flow | -91.53M |
| FCF Per Share | -1.08 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TNYA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TNYA is $5.5, which is 957.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.5 |
| Price Target Difference | 957.7% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -6.76 |
| Piotroski F-Score | 1 |